Lunsumio (mosunetuzumab-axgb)

Lunsumio (mosunetuzumab-axgb) is a bispecific antibody that targets B cells and is used to treat follicular lymphoma in adult patients who have received at least two prior lines of therapy. It was approved by the EMA in June 2022 and by the FDA in December 2022